COG ADVL0413: A PHASE I STUDY OF THE RAF KINASE AND RECEPTOR TYROSINE KINASE

COG ADVL0413：RAF 激酶和受体酪氨酸激酶的 I 期研究

• 批准号: 7603585
• 负责人: JULIE R PARK
• 金额: $ 0.03万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603585
• 关键词: Adult; Adverse effects; BAY 54-9085; Blood Cells; Blood specimen; Child; Computer Retrieval of Information on Scientific Projects Database; Correlative Study; Deglutition; Dose; Drug Kinetics; Funding; Goals; Grant; Institution; Learning; Liquid substance; Malignant neoplasm of kidney; Patients; Pediatric Neoplasm; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Protein Tyrosine Kinase; Proteins; Refractory; Renal carcinoma; Research; Research Personnel; Resources; Safety; Signal Transduction; Solid Neoplasm; Source; Tablets; Testing; Thinking; United States Food and Drug Administration; United States National Institutes of Health; Work; day; leukemia; neoplastic cell; raf Kinases; receptor; tumor growth

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This phase I study tests the safety of a drug called sorafenib (BAY43-9006) in children with refractory solid tumors or refractory leukemia. Sorafenib works by blocking proteins which are thought to be important for signaling tumor growth. Sorafenib recently received FDA approval for treatment of advanced kidney cancer which occurs mostly in adults. The goals of this study are to find the highest safe dose of Sorafenib that can be given to children with solid tumors without causing severe side effects, to find out if the highest safe dose of Sorafenib in children with solid tumors is also safe for children with leukemia, and to learn what kind of side effects Sorafenib can cause. Other goals of this study include learning how the body handles the drug, learning what effects Sorafenib has on blood cells and tumor cells, and learning more about whether Sorafenib may be a beneficial treatment for pediatric tumors. The patients will be given Sorafenib twice a day. Up to 24-28 day courses of treatment may be given. Sorafenib tablets must be swallowed whole with clear liquids. In addition to these tests, patients will be the given the option to have blood samples taken during the first course of therapy for pharmacokinetics and correlative studies. Optional studies also include DEMRIs. Once the maximum dose is found in patients with solid tumors, a group of children with refractory leukemia will be given Sorafenib at this dose.

这个子项目是众多研究子项目之一